Increased Levels of Circulating IL-16 and Apoptosis Markers Are Related to the Activity of Whipple's Disease

PLoS ONE

Volumn 2, Issue 6, 2007, Pages

  Benoit, Marie ^a   Fenollar, Florence ^a   Raoult, Didier ^a   Mege, Jean Louis ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CASPASE; INTERLEUKIN 16;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; INTESTINE LIPODYSTROPHY; LONGITUDINAL STUDY; MALE; METABOLISM; MIDDLE AGED; NUCLEOSOME; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; APOPTOSIS; CASE-CONTROL STUDIES; CASPASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-16; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NUCLEOSOMES; SENSITIVITY AND SPECIFICITY; WHIPPLE DISEASE;

EID: 37549035649     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000494     Document Type: Article

References (42)

1. Whipple GH, (1907) A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues. Bull Johns Hopkins Hosp 18: 382-391.
2. Fenollar F, Raoult D, (2001) Whipple's disease. Clin Diagn Lab Immunol 8: 1-8.
3. Marth T, Raoult D, (2003) Whipple's disease. Lancet 361: 239-246.
4. Durand DV, Lecomte C, Cathebras P, Rousset H, Godeau P, (1997) Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Société Nationale Française de Médecine Interne. Medicine (Baltimore) 76: 170-184.
5. Maizel H, Ruffin JM, Dobbins WO 3rd, (1970) Whipple's disease: a review of 19 patients from one hospital and a review of the literature since 1950. Medicine (Baltimore) 49: 175-205.
6. Yardley JH, Hendrix TR, (1961) Combined electron and light microscopy in Whipple's disease. Demonstration of "bacillary bodies" in the intestine. Bull Johns Hopkins Hosp 109: 80-98.
7. Relman DA, Schmidt TM, MacDermott RP, Falkow S, (1992) Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 327: 293-301.
8. Raoult D, Birg ML, La Scola B, Fournier PE, Enea M, et al.(2000) Cultivation of the bacillus of Whipple's disease. N Engl J Med 342: 620-625.
9. La Scola B, Fenollar F, Fournier PE, Altwegg M, Mallet MN, et al.(2001) Description of Tropheryma whipplei gen. nov., sp. nov., the Whipple's disease bacillus. Int J Syst Evol Microbiol 51: 1471-1479.
10. Bentley SD, Maiwald M, Murphy LD, Pallen MJ, Yeats CA, et al.(2003) Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whipplei. Lancet 361: 637-644.
11. Raoult D, Ogata H, Audic S, Robert C, Suhre K, et al.(2003) Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome. Genome Res 13: 1800-1809.
12. Fenollar F, Fournier PE, Robert C, Raoult D, (2004) Use of genome selected repeated sequences increases the sensitivity of PCR detection of Tropheryma whipplei. J Clin Microbiol 42: 401-403.
13. Marth T, Fredericks D, Strober W, Relman DA, (1996) Limited role for PCR-based diagnosis of Whipple's disease from peripheral blood mononuclear cells. Lancet 348: 66-67.
14. Singer R, (1998) Diagnosis and treatment of Whipple's disease. Drugs 55: 699-704.
15. Desnues B, Lepidi H, Raoult D, Mege JL, (2005) Whipple disease: intestinal infiltrating cells exhibit a transcriptional pattern of M2/alternatively activated macrophages. J Infect Dis 192: 1642-1646.
16. Desnues B, Raoult D, Mege JL, (2005) IL-16 is critical for Tropheryma whipplei replication in Whipple's disease. J Immunol 175: 4575-4582.
17. Zhang Y, Center DM, Wu DM, Cruikshank WW, Yuan J, et al.(1998) Processing and activation of pro-interleukin-16 by caspase-3. J Biol Chem 273: 1144-1149.
18. Cruikshank WW, Kornfeld H, Center DM, (2000) Interleukin-16. J Leukoc Biol 67: 757-766.
19. Elssner A, Doseff AI, Duncan M, Kotur M, Wewers MD, (2004) IL-16 is constitutively present in peripheral blood monocytes and spontaneously released during apoptosis. J Immunol 172: 7721-7725.
20. Wu DM, Zhang Y, Parada NA, Kornfeld H, Nicoll J, et al.(1999) Processing and release of IL-16 from CD4+ but not CD8+ T cells is activation dependent. J Immunol 162: 1287-1293.
21. Laberge S, Cruikshank WW, Kornfeld H, Center DM, (1995) Histamine-induced secretion of lymphocyte chemoattractant factor from CD8+ T cells is independent of transcription and translation. Evidence for constitutive protein synthesis and storage. J Immunol 155: 2902-2910.
22. Lim KG, Wan HC, Bozza PT, Resnick MB, Wong DT, et al.(1996) Human eosinophils elaborate the lymphocyte chemoattractants IL-16 (lymphocyte chemoattractant factor) and RANTES. J Immunol 156: 2566-2570.
23. Rumsaeng V, Cruikshank WW, Foster B, Prussin C, Kirshenbaum AS, et al.(1997) Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J Immunol 159: 2904-2910.
24. Fenollar F, Lepidi H, Gerolami R, Drancourt M, Raoult D, (2003) Whipple disease associated with giardiasis. J Infect Dis 188: 828-834.
25. Lepidi H, Fenollar F, Gerolami R, Mege JL, Bonzi MF, et al.(2003) Whipple's disease: immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. Hum Pathol 34: 589-596.
26. Lepidi H, Fenollar F, Dumler JS, Gauduchon V, Chalabreysse L, et al.(2004) Cardiac valves in patients with Whipple endocarditis: microbiological, molecular, quantitative histologic, and immunohistochemical studies of 5 patients. J Infect Dis 190: 935-945.
27. Fenollar F, Puechal X, Raoult D, (2007) Whipple's disease. N Engl J Med 356: 55-66.
28. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, et al.(2006) European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 (Suppl 1): i16-35.
29. Capo C, Lindberg FP, Meconi S, Zaffran Y, Tardei G, et al.(1999) Subversion of monocyte functions by Coxiella burnetii: impairment of the cross-talk between αvβ3 integrin and CR3. J Immunol 163: 6078-6085.
30. Fournier PE, Marrie TJ, Raoult D, (1998) Diagnosis of Q fever. J Clin Microbiol 36: 1823-1834.
31. Ehrbar HU, Bauerfeind P, Dutly F, Koelz HR, Altwegg M, (1999) PCR-positive tests for Tropheryma whippelii in patients without Whipple's disease. Lancet 353: 2214.
32. Street S, Donoghue HD, Neild GH, (1999) Tropheryma whippelii DNA in saliva of healthy people. Lancet 354: 1178-1179.
33. Holdenrieder S, Stieber P, Chan LY, Geiger S, Kremer A, et al.(2005) Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem 51: 1544-1546.
34. Blaschke S, Schulz H, Schwarz G, Blaschke V, Muller GA, et al.(2001) Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol 28: 12-21.
35. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, et al.(2001) Increased expression of IL-16 in inflammatory bowel disease. Gut 48: 326-332.
36. Middel P, Reich K, Polzien F, Blaschke V, Hemmerlein B, et al.(2001) Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease. Gut 49: 795-803.
37. Skundric DS, Zhou W, Cruikshank WW, Dai R, (2005) Increased levels of bioactive IL-16 correlate with disease activity during relapsing experimental autoimmune encephalomyelitis (EAE). J Autoimmun 25: 206-214.
38. Skundric DS, Cai J, Cruikshank WW, Gveric D, (2006) Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflammation 3: 13.
39. Belloni Fortina A, Tonin E, Pigozzi B, Romano I, Michelotto G, et al.(2006) IL-16 serum level in children with atopic dermatitis. Int J Immunopathol Pharmacol 19: 841-845.
40. Maiwald M, Schuhmacher F, Ditton HJ, von Herbay A, (1998) Environmental occurrence of the Whipple's disease bacterium (Tropheryma whippelii). Appl Environ Microbiol 64: 760-762.
41. Mahnel R, Marth T, (2004) Progress, problems, and perspectives in diagnosis and treatment of Whipple's disease. Clin Exp Med 4: 39-43.
42. Skundric DS, Dai R, Zakarian VL, Bessert D, Skoff RP, et al.(2005) Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res 79: 680-693.